State Street
SNDX icon

State Street’s Syndax Pharmaceuticals SNDX Stock Holding History

State Street’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103M Sell
4,430,076
-166,476
-4% -$3.62M ﹤0.01% 1356
2025
Q4 		$96.6M Buy
4,596,552
+743,003
+19% +$13M ﹤0.01% 1380
2025
Q3 		$59.3M Buy
3,853,549
+410,797
+12% +$5.38M ﹤0.01% 1641
2025
Q2 		$32.2M Sell
3,442,752
-528,980
-13% -$5.82M ﹤0.01% 1924
2025
Q1 		$48.8M Buy
3,971,732
+54,216
+1% +$765K ﹤0.01% 1652
2024
Q4 		$51.8M Buy
3,917,516
+146,690
+4% +$2.51M ﹤0.01% 1702
2024
Q3 		$72.6M Buy
3,770,826
+148,491
+4% +$3.07M ﹤0.01% 1509
2024
Q2 		$74.4M Sell
3,622,335
-1,197,259
-25% -$25.1M ﹤0.01% 1448
2024
Q1 		$115M Sell
4,819,594
-196,630
-4% -$4.39M 0.01% 1216
2023
Q4 		$108M Buy
5,016,224
+1,415,576
+39% +$21.8M 0.01% 1240
2023
Q3 		$52.3M Sell
3,600,648
-553,413
-13% -$10.5M ﹤0.01% 1598
2023
Q2 		$86.9M Buy
4,154,061
+287,831
+7% +$5.99M ﹤0.01% 1318
2023
Q1 		$81.7M Buy
3,866,230
+217,767
+6% +$5.42M ﹤0.01% 1319
2022
Q4 		$92.9M Buy
3,648,463
+1,031,026
+39% +$24M 0.01% 1201
2022
Q3 		$62.9M Buy
2,617,437
+181,920
+7% +$4.08M ﹤0.01% 1436
2022
Q2 		$46.9M Buy
2,435,517
+55,180
+2% +$919K ﹤0.01% 1688
2022
Q1 		$41.4M Sell
2,380,337
-99,867
-4% -$1.68M ﹤0.01% 1889
2021
Q4 		$54.3M Buy
2,480,204
+376,757
+18% +$6.96M ﹤0.01% 1751
2021
Q3 		$40.2M Sell
2,103,447
-1,066,985
-34% -$17.8M ﹤0.01% 1972
2021
Q2 		$54.4M Buy
3,170,432
+516,961
+19% +$9.47M ﹤0.01% 1781
2021
Q1 		$59.3M Buy
2,653,471
+953,751
+56% +$21.5M ﹤0.01% 1613
2020
Q4 		$37.8M Buy
1,699,720
+581,000
+52% +$12M ﹤0.01% 1820
2020
Q3 		$16.5M Buy
1,118,720
+645,600
+136% +$9.84M ﹤0.01% 2144
2020
Q2 		$7.01M Buy
473,120
+33,218
+8% +$506K ﹤0.01% 2595
2020
Q1 		$4.83M Sell
439,902
-633
-0.1% -$5.94K ﹤0.01% 2645
2019
Q4 		$3.87M Buy
440,535
+24,971
+6% +$183K ﹤0.01% 2964
2019
Q3 		$3.1M Buy
415,564
+91,018
+28% +$829K ﹤0.01% 3035
2019
Q2 		$3.02M Buy
324,546
+81,628
+34% +$595K ﹤0.01% 3067
2019
Q1 		$1.27M Buy
242,918
+24,266
+11% +$138K ﹤0.01% 3288
2018
Q4 		$973K Buy
218,652
+22,794
+12% +$125K ﹤0.01% 3333
2018
Q3 		$1.58M Buy
195,858
+41,851
+27% +$298K ﹤0.01% 3325
2018
Q2 		$1.08M Buy
154,007
+24,066
+19% +$236K ﹤0.01% 3392
2018
Q1 		$1.85M Buy
129,941
+13,651
+12% +$145K ﹤0.01% 3199
2017
Q4 		$1.02M Buy
116,290
+31,756
+38% +$314K ﹤0.01% 3352
2017
Q3 		$991K Buy
84,534
+3,207
+4% +$39.3K ﹤0.01% 3379
2017
Q2 		$1.14M Buy
81,327
+20,106
+33% +$230K ﹤0.01% 3311
2017
Q1 		$841K Buy
61,221
+2,300
+4% +$23.9K ﹤0.01% 3301
2016
Q4 		$422K Buy
58,921
+3,599
+7% +$39.4K ﹤0.01% 3413
2016
Q3 		$840K Buy
55,322
+9,776
+21% +$129K ﹤0.01% 3225
2016
Q2 		$448K Buy
+45,546
New +$625K ﹤0.01% 3404

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street's SNDX Position: Q1 2026 in Review

State Street reduced its Syndax Pharmaceuticals (SNDX) stake by 3.6% in Q1 2026, selling an estimated $3.62M and leaving 4,430,076 shares worth $103M. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

State Street first reported a position in SNDX in Q2 2016 and has held it in 40 quarters since. The position peaked at $115M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • State Street held 4,430,076 shares of Syndax Pharmaceuticals worth $103M as of Q1 2026.
  • State Street sold 166,476 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.62M.
  • Syndax Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1356 holding.
  • State Street first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • State Street's Syndax Pharmaceuticals position peaked at $115M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.